TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01647334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Study: NCT03652467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TACE
Description: Conventional chemoembolization drugs are injected through hepatic artery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine and conventional TACE
Description: Deferoxamine is injected before conventional transarterial chemoembolization.
Study: NCT00902174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to imatinib 100 mg film coated tablets
Study: NCT01833000

Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
Study: NCT02095509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug class: Low-molecular weight heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug class: Low-molecular weight heparin
Study: NCT03930407

Intervention type: PROCEDURE
Intervention: The Hayman uterine compression suture.
Description: Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
Study: NCT02288988

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Antireflux Surgery
Description: Collis gasytroplasty Nissen antireflux fundoplication
Study: NCT03339973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-PAOD
Description: Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection in pre-filled syringe
Study: NCT03106467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic appendectomy
Description: Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port laparoscopic appendectomy
Description: Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
Study: NCT03536026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional bronchoscopy
Description: -Standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIDA Pulmonary Workstation 2
Description: -Virtual bronchoscopic navigation system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Standard of care
Study: NCT01518504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Mobilization
Description: The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
Study: NCT03403309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1) Inosine 5'-monophosphate
Description: 1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
Study: NCT01009645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact and Myth Educational Message
Description: Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact, Myth, Why Educational Message
Description: Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Educational Message
Description: Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
Study: NCT01105429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 150 mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 300 mg, once daily, 1 day
Study: NCT02251210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06135610

Intervention type: DIAGNOSTIC_TEST
Intervention: Postive SAR-CoV-2 PCR nasopharyngeal swab
Description: Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
Study: NCT00517569

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GX-12
Description: a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
Study: NCT00480870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1p / day for 1 month and 2 / day for 5 months on
Study: NCT02266212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5 ml arterial blood
Description: A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5 ml arterial blood
Description: A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5 ml arterial blood
Description: A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
Study: NCT06380010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet group
Description: Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
Study: NCT02303106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Study: NCT05296031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions
Description: Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions
Description: Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
Study: NCT03762447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
Study: NCT02090361

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin graft
Description: Epidermization of the defect by applying a thin layer of autologous epidermis
Study: NCT01105429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, (TBD), once daily, 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day
Study: NCT02090361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin graft
Description: Epidermization of the defect by applying a thin layer of autologous epidermis
Study: NCT02705274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation (full session completed within 42 days).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation (full session completed within 42 days).
Study: NCT01371045

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
Study: NCT02024126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Exercise therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Exercise therapy
Study: NCT03139617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Compartment Block (FICB)
Description: The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 in 1 femoral block (FNB)
Description: The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood .
Study: NCT04076995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water Intake
Description: Increased water intake during the 11 h protocol
Study: NCT03775564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REMEDRUGBY PROGRAM
Description: * 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOUCH RUGBY PROGRAM
Description: Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual
Study: NCT04474314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687
Study: NCT04167007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
Study: NCT01105429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day
Study: NCT00525668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epigallocatechin-gallate (Sunphenon)
Description: 200 mg twice daily, after 3 months 400 mg twice daily
Study: NCT02539576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC FDC tablet
Description: ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally.
Study: NCT03443206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anonymous social support
Description: Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
Study: NCT00525668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
Study: NCT04324801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeostatic plasticity induction using transcranial direct current stimulation
Description: Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
Study: NCT03443206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation
Description: educational materials related to mental health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: educational materials related to mental health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online resources
Description: links to online mental health resources
Study: NCT01771146

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRINOX Regimen
Description: 6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
Study: NCT03181854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone coaching
Description: Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation with PCT doctor
Description: Consultation with PCT physician every 3 weeks.
Study: NCT00142870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: 150 mg, twice a day
Study: NCT02635516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Phototherapy
Description: The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized.
Study: NCT02177448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR277 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR277 medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR277 high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril medium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BIBR277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching enalapril
Study: NCT03031808

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine spray (2%)
Description: Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes

Intervention type: DRUG
Group type: OTHER
Intervention: Muscle Relaxant (Rocuronium)
Description: After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.

Intervention type: OTHER
Group type: OTHER
Intervention: No Muscle relaxant, no Lidocaine
Description: This group get general anesthesia without Rocuronium or Lidocaine
Study: NCT03887000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Fibromyalgia patients taking either magnesium or placebo according to the randomized plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Fibromyalgia patients taking either magnesium or placebo according to the randomized plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Fibromyalgia patients taking either magnesium or placebo according to the randomized plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Fibromyalgia patients taking either magnesium or placebo according to the randomized plan